Moderna–Wells Fargo: investor conference, 202109 supply service Moderna presents at Wells Fargo 2021 Virtual Healthcare Conference

	Period	2021-09-10
	Partner, 1st	Moderna Inc. (Nasdaq: MRNA)
	Group	Moderna (Group)
	Partner, 2nd	Wells Fargo Securities LLC
	Group	Wells Fargo (Group)
	Product	Wells Fargo Healthcare Conference 2021 DIGITAL
	Product 2	mRNA technology

Moderna, Inc.. (9/2/21). "Press Release: Moderna to Present at Upcoming Investor Conferences in September 2021". Cambridge, MA.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

> Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 10:00 a.m. ET

> Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 11:45 a.m. ET

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 23 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com